Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ra Pharma’s zilucoplan meets primary endpoints in phase 2 gMG trial
Ra Pharmaceuticals’ (Ra Pharma) zilucoplan has succeeded in a phase 2 trial in generalized myasthenia gravis (gMG) by meeting the primary and key secondary end points.
Clinical Trials
-
12 Dec 2018
-
11 Dec 2018
BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers
Bristol-Myers Squibb will evaluate Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a live biotherapeutic product (LBP), in patients with advanced or metastatic cancers.
-
10 Dec 2018
Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease
Eisai said that the first investigational drug candidate from its drug discovery collaboration with University College London (UCL) is set to enter Phase I clinical trials for Alzheimer's disease (AD) in early 2019.
-
10 Dec 2018
AstraZeneca’s Imfinzi fails to improve OS in head and neck cancer trial
AstraZeneca said that the combination of its Imfinzi (durvalumab) monotherapy and tremelimumab has failed to improve overall survival (OS) rate compared to standard-of-care (SoC) chemotherapy in a head and neck cancer trial.
-
05 Dec 2018
Novartis initiates phase III trials of ligelizumab in urticaria
Novartis has initiated phase III trials for its monoclonal anti-IgE antibody ligelizumab (QGE031) in chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.
-
05 Dec 2018
Ixico secures expanded contract from major biopharmaceutical firm
Data analytics company Ixico has signed an expanded scope to an existing contract with a top 10 biopharmaceutical company.
-
05 Dec 2018
J&J’s Darzalex reduces disease progression in multiple myeloma study
Johnson & Johnson’s (J&J) Darzalex (daratumumab), in combination with lenalidomide and dexamethasone (Rd), has significantly reduced the risk of disease progression in multiple myeloma study.
-
28 Nov 2018
Vedanta Biosciences starts phase 1 study of VE202 to treat IBD
US-based Vedanta Biosciences has started a phase I clinical study of its live biotherapeutic product (LBP) candidate VE202 to treat inflammatory bowel disease (IBD).
-
28 Nov 2018
QPS extends US phase I clinical trial capabilities
Contract research organization (CRO) QPS has expanded its US-based phase I clinical trial capabilities to support the increasing requirements of its pharmaceutical, biotechnology and CRO partners.
-
27 Nov 2018
BMS’ Opdivo plus Yervoy fails to improve OS in lung cancer study
Bristol-Myers Squibb (BMS) announced that its cancer drug combination Opdivo plus Yervoy has failed to improve overall survival (OS) rate in the phase 3 CheckMate -451 study.